Sign in Subscribe

Alex Chompff

Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models

Skip to content The CRC Digest ▸ TREATMENT Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models Fruquintinib, an oral inhibitor of all three vascular endothelial growth factor receptors that has been approved for chemorefractory CRC, showed combined antitumor activity with TAS-102 in xenograft

Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status

Skip to content The CRC Digest ◆ TRIAL DATA Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from

Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery

Skip to content The CRC Digest ▪ SCREENING Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery The randomized trial found that circulating tumor DNA methylation monitoring identified recurrent metastatic disease with a more favorable and potentially resectable anatomical profile, significantly increasing the

CRC Research Update — July 30, 2026

Today's colorectal cancer research highlights

KRAS mutations drive immune evasion through RNA modifications

Skip to content The CRC Digest ◇ RESEARCH KRAS mutations drive immune evasion through RNA modifications Preclinical research found that KRAS mutations remodel RNA m6A modifications to increase CD73 expression, promoting immune evasion in colorectal cancer. (Cancer Research) This content is informational only and does not constitute medical advice. Always consult

Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology) This content is

Multi-cancer blood tests may not match colonoscopy for colorectal cancer prevention

Skip to content The CRC Digest ▪ SCREENING Multi-cancer blood tests may not match colonoscopy for colorectal cancer prevention A modeling study found that multi-cancer early detection blood tests offer little opportunity for cancer prevention through precursor lesion removal, raising questions about whether detecting multiple cancers can offset the loss of

Blood-based surveillance after surgery increased curative treatment for recurrence

Skip to content The CRC Digest ▪ SCREENING Blood-based surveillance after surgery increased curative treatment for recurrence The phase III FIND trial showed that ctDNA methylation-guided surveillance in nonmetastatic colorectal cancer patients after surgery led to higher rates of curative-intent therapy for recurrence compared to standard CT-based monitoring. (Journal of Clinical

Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to

CRC Research Update — July 28, 2026

Today's colorectal cancer research highlights